Abstract

1. To review all Group protocols and concept sheets involving chemotherapy and biologic response modifiers during their preparation. 2. To introduce a program of population pharmacokinetics to a Cooperative Group setting. 3. To introduce a program of biotherapy into CALGB. 4. To review toxicities encountered during the course of Group studies. 5. To introduce new drugs and new combinations of established drugs into Group studies: in Phase II studies, and then, if indicated, Phase III comparative trials. 6. To conduct disease protocols for tumors or diseases not covered by other CALGB committees, e.g. Intergroup studies and pharmacology companion protocols. 7. To provide research symposia at Group meetings.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA044691-04
Application #
3558536
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1986-04-01
Project End
1993-03-31
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
4
Fiscal Year
1989
Total Cost
Indirect Cost

  Institution

Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201

  Publications

Lewis, Lionel D; Miller, Antonius A; Owzar, Kouros et al. (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29-33
Lewis, Lionel D; Miller, Antonius A; Rosner, Gary L et al. (2007) A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13:3302-11
Klein, Cheri E; Kastrissios, Helen; Miller, Antonius A et al. (2006) Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 57:199-206
Miller, Antonius A; Rosner, Gary L; Egorin, Merrill J et al. (2004) Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 10:8325-31
Akerley, Wallace; Herndon, James E; Egorin, Merrill J et al. (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-6
Rosner, Gary L; Stadler, Walter; Ratain, Mark J (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-84
Fleming, Gini F; Meropol, Neal J; Rosner, Gary L et al. (2002) A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 8:3718-27
Jodrell, D I; Murray, L S; Hawtof, J et al. (1996) A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemother Pharmacol 37:356-62
Kearns, C M; Gianni, L; Egorin, M J (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23
Ratain, M J; Rosner, G; Allen, S L et al. (1995) Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 13:741-7

Showing the most recent 10 out of 20 publications